a84538

Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Ritonavir-13C-D3 is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir (T1525) is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Ritonavir-13C-D3 (Standard) is a reference standard of Ritonavir-13C-D3 intended for quantitative analysis, quality control, and related biochemical research applications. Ritonavir-13C-d3 the 13C and deuterated compound of Ritonavir. Ritonavir has a CAS number of 155213-67-5. Ritonavir is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

Ritonavir (Standard) is a reference standard for research and analysis in studies involving Ritonavir. Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.

rel-Ritonavir-D6 is a deuterated form of Ritonavir. Ritonavir (ABT 538) serves as an inhibitor of HIV protease, utilized in studies of HIV infection and AIDS. Additionally, Ritonavir acts as an inhibitor of SARS-CoV 3CLpro, with an IC50 of 1.61 μM.

Ritonavir-D6 is the deuterated form of Ritonavir. Ritonavir (T1525) (ABT 538) serves as an inhibitor of the HIV protease, primarily utilized in the study of HIV infection and AIDS. Additionally, Ritonavir (T1525) acts as an inhibitor of SARS-CoV 3CLpro, with an IC50 of 1.61 μM.